logo
Bioventus Inc. Reports Net Loss of $142.8 Million in Second Quarter of 2023

Bioventus Inc. Reports Net Loss of $142.8 Million in Second Quarter of 2023

Company's Q2 2023 Revenue Declines to $137.1 Million Amidst Challenging Financial Period

By USInMinutes
Published - Aug 08, 2023, 10:25 AM ET
Last Updated - Aug 08, 2023, 10:26 AM EDT

Bioventus Inc.(BVS), a leading medical d evice company specializing in orthobiologic solutions, has reported its financial results for the second quarter of 2023, revealing a net loss of $142.8 million. The company faced a challenging financial period as its revenue for the quarter decreased to $137.1 million compared to $140.3 million in the same period last year.

Net Loss in Q2 2023

During the three months ended July 1, 2023, Bioventus Inc. experienced a net loss of $142.8 million. This figure represents a significant decrease in financial performance compared to the same period in 2022 when the company reported a net loss of $7.3 million.

Revenue Decline to $137.1 Million

Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024